Topoisomerase I inhibitors: camptothecins and beyond. Export

@article{citeulike:862121, abstract = {Nuclear DNA topoisomerase I (TOP1) is an essential human enzyme. It is the only known target of the alkaloid camptothecin, from which the potent anticancer agents irinotecan and topotecan are derived. As camptothecins bind at the interface of the TOP1–DNA complex, they represent a paradigm for interfacial inhibitors that reversibly trap macromolecular complexes. Several camptothecin and non-camptothecin derivatives are being developed to further increase anti-tumour activity and reduce side effects. The mechanisms and molecular determinants of tumour response to TOP1 inhibitors are reviewed, and rational combinations of TOP1 inhibitors with other drugs are considered based on current knowledge of repair and checkpoint pathways that are associated with TOP1-mediated DNA damage.}, author = {Pommier, Yves}, citeulike-article-id = {862121}, citeulike-linkout-0 = {http://dx.doi.org/10.1038/nrc1977}, citeulike-linkout-1 = {http://dx.doi.org/10.1038/nrc1977}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/16990856}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=16990856}, doi = {10.1038/nrc1977}, issn = {1474-175X}, journal = {Nature reviews. Cancer}, keywords = {cepa, topo}, month = {October}, number = {10}, pages = {789--802}, posted-at = {2009-01-27 12:22:16}, priority = {2}, publisher = {Nature Publishing Group}, title = {Topoisomerase I inhibitors: camptothecins and beyond.}, url = {http://dx.doi.org/10.1038/nrc1977}, volume = {6}, year = {2006} }

TY - JOUR ID - citeulike:862121 L3 - citeulike-article-id:862121 N2 - Nuclear DNA topoisomerase I (TOP1) is an essential human enzyme. It is the only known target of the alkaloid camptothecin, from which the potent anticancer agents irinotecan and topotecan are derived. As camptothecins bind at the interface of the TOP1–DNA complex, they represent a paradigm for interfacial inhibitors that reversibly trap macromolecular complexes. Several camptothecin and non-camptothecin derivatives are being developed to further increase anti-tumour activity and reduce side effects. The mechanisms and molecular determinants of tumour response to TOP1 inhibitors are reviewed, and rational combinations of TOP1 inhibitors with other drugs are considered based on current knowledge of repair and checkpoint pathways that are associated with TOP1-mediated DNA damage. IS - 10 JF - Nature reviews. Cancer SN - 1474-175X EP - 802 TI - Topoisomerase I inhibitors: camptothecins and beyond. PB - Nature Publishing Group VL - 6 SP - 789 KW - cepa KW - topo AU - Pommier, Yves PY - 2006/10// UR - http://dx.doi.org/10.1038/nrc1977 ER -